Short answer
Not close enough to plan a life around. As of September 18, 2026, every genital-herpes vaccine candidate registered on ClinicalTrials.gov sits in Phase 1 or Phase 1/2: BioNTech's BNT163 lists primary completion in October 2026, and Moderna's therapeutic mRNA-1608 finished its Phase 1/2 in April 2025 with no efficacy results posted in the record we read. The only completed Phase 3 belongs to pritelivir, an antiviral for drug-resistant HSV in immunocompromised patients. Gene editing has reached a human trial for an HSV eye infection, not for genital herpes. The tools that exist today are daily antivirals and condoms.
Checked September 18, 2026 · Sources: ClinicalTrials.gov, NEJM, listed at the end · This site is run by an employee of the company that owns PositiveSingles. Why that matters
Where things stand
Three different things get called "a cure" in headlines, and they are on very different clocks. Treatments suppress the virus while you take them; that shelf is stocked now. Vaccines would prevent or reduce infection or outbreaks; that shelf is in early human trials. An actual cure would clear the latent virus from the nerve cells where it sleeps; for genital herpes, that shelf is empty of registered human trials.
Everything on this page comes with a trial identifier you can check yourself, because that is the rule here: if a program has no NCT number, it does not appear, however exciting the press release. All rows were read on the registry on September 18, 2026, and the statuses are the registry's own words.
The vaccine pipeline
| Candidate | Sponsor | Phase | Registry status | Primary completion | Trial ID |
|---|---|---|---|---|---|
| BNT163 | BioNTech SE | Phase 1 | Active, not recruiting | October 2026 | NCT05432583 |
| mRNA-1608 | ModernaTX | Phase 1/2 | Completed | April 25, 2025 | NCT06033261 |
| unnamed candidate | Changchun BCHT Biotechnology | Phase 1 | Enrolling by invitation | March 2027 | NCT07330440 |
What the table cannot say is whether any of them work; none has posted efficacy data in the records we read. BNT163 is safety, tolerability, and immunogenicity in healthy volunteers and volunteers with recurrent genital herpes. mRNA-1608 is an mRNA therapeutic candidate vaccine for adults with recurrent genital herpes; no efficacy results posted with the record we read. The third is an mRNA vaccine against HSV-2; listed start October 13, 2025. A candidate that clears Phase 1 still has Phase 2, Phase 3, and review between it and a pharmacy, a road that in this field has taken decades and eaten every traveler so far.
The actual cure question
A cure means removing or permanently silencing the virus that sits latent in nerve cells, and gene editing is the technology most often attached to that hope. Here is what the registry actually holds: Shanghai BDgene's BD111, a gene-editing candidate, is in a Phase 2a trial (NCT06474442, recruiting, primary completion December 2026) for HSV-1 stromal keratitis, an eye infection. That is a genuine first for the field, and it is not genital herpes.
Our registry search on September 18, 2026 found no registered human trial of a gene-editing or other curative candidate for genital HSV. Laboratory work exists and is real science, but a therapy that has not entered a registered human trial is, on any honest timeline, years from a prescription pad. When that first genital-herpes cure trial registers, this page will carry its number.
Why the caution
The field has been within sight of a vaccine before. The Herpevac trial (NCT00057330) randomized 8,323 women and reported in 2012: overall efficacy against genital herpes disease was 20% (95% CI, -29 to 50), which is to say none demonstrated. It did show 58% (95% CI, 12 to 80) efficacy against HSV-1 genital disease, and none against HSV-2 infection (-8% (95% CI, -59 to 26)). That is what a Phase 3 heartbreak looks like in numbers, and it is why a promising Phase 1 deserves interest without a countdown clock.
What to do meanwhile
The unglamorous answer is that the tools available today already move the numbers a vaccine would be judged against. In the couples trial, daily valacyclovir cut transmission from 27 of 741 couples to 14 of 743 over 8 months; pooled condom studies cut acquisition by roughly 30%. Our transmission guide holds those numbers with their denominators.
And do not park your dating life in the waiting room. People have built relationships with this virus for as long as it has had a name, without a pipeline's permission. If the diagnosis is fresh, start with dating after a diagnosis; if what you want is a pool where the conversation is already had, that exists today too.
Sources
- ClinicalTrials.gov registry records. All trial rows above: NCT05432583, NCT06033261, NCT07330440, NCT03073967, NCT06385327, NCT06698575, NCT04979975, NCT06474442, and the expanded-access listing NCT05844436. Conditions, phases, statuses, and dates as the registry listed them on September 18, 2026.
- Belshe RB et al., New England Journal of Medicine (the Herpevac trial). 8,323 women; overall efficacy 20% (95% CI, -29 to 50); HSV-1 genital disease 58% (95% CI, 12 to 80); HSV-2 infection -8% (95% CI, -59 to 26); Belshe RB et al. N Engl J Med. 2012;366(1):34-43. Abstract read September 18, 2026. Trial NCT00057330.
- Corey L et al., New England Journal of Medicine. Once-daily valacyclovir and HSV-2 transmission in 1,484 discordant couples over 8 months: 27 of 741 versus 14 of 743.
- Martin ET et al., pooled condom analysis. 6 studies, 5,384 participants; hazard ratio 0.7.